An independent Data Monitoring Committee (DMC) completed a safety review following adverse events identified in the BX004 Phase 2b trial and recommended that the study continue with revised dosing ...
Summary • BiomX Inc. (PHGE) stock fell 13% in pre-market trading, dropping to $5.00 from $5.78.• The decline follows an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback